AVE 0991 sodium salt
Based on 15 publication(s) in Google Scholar
AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50 of 21 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.47%
- CAS No.: 306288-04-0
- Formule: C29H31N4NaO5S2
- Masse moléculaire:602.70
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Covalent Screening Library
HY-L036
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Endocrinology Compound Library
HY-L047
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Angiogenesis-Related Compound Library
HY-L088
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) AVE 0991 sodium salt
More- J Hepatol. 2022 Nov 9;S0168-8278(22)03285-8. [Abstract]
- Blood. 2015 Jan 22;125(4):710-9. [Abstract]
- Metabolism. 2025 Apr 29:156275. [Abstract]
- Redox Biol. 2019 Jan;20:75-86. [Abstract]
- Diabetes. 2017 Aug;66(8):2201-2212. [Abstract]
- Biochem Pharmacol. 2024 Jun:224:116261. [Abstract]
- Front Aging Neurosci. 2021 Feb 15:13:624387. [Abstract]
- J Inflamm Res. 2021 Dec 18;14:7007-7019. [Abstract]
- Sci Rep. 2024 Nov 1;14(1):26346. [Abstract]
- Aging (Albany NY). 2018 Apr 17;10(4):645-657. [Abstract]
- PLoS One. 2015 Nov 5;10(11):e0142087. [Abstract]
- Exp Anim. 2022 Nov 10;71(4):519-528. [Abstract]
- SSRN. 2025 Jun 2.
- Res Sq. 2024 Aug 10.
- Research Square Preprint. 2021 Nov.
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
Voir tous les produits spécifiques à Isoform Angiotensin Receptor
More
Activité biologique
IC50: 21±35 nM (Ang-(1-7) receptor)[1]
AVE 0991 is a nonpeptide compound that evokes effects similar to Ang-(1-7) on the endothelium. AVE 0991 and unlabeled Ang-(1-7) compete for high-affinity binding of [125I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC50s of 21±35 and 220±280 nM, respectively. Peak concentrations of NO and O2- release by AVE 0991 sodium salt and Ang-(1-7) (both 10 μM) are not significantly different (NO: 295±20 and 270±25 nM; O2-: 18±2 and 20±4 nM). However, the released amount of bioactive NO is ≈5 times higher for AVE 0991 in comparison to Ang-(1-7)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 306288-04-0
-
Appearance Solid
-
Masse moléculaire 602.70
-
Formule C29H31N4NaO5S2
-
Color White to yellow
-
SMILES
O=S(C1=C(C2=CC=C(CN3C(C=O)=C(OC)N=C3C4=CC=CC=C4)C=C2)C=C(CC(C)C)S1)([N-]C(NCC)=O)=O.[Na+]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
J Hepatol
Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice. [Abstract]2022 Nov 9;S0168-8278(22)03285-8. PMID: 36368597 -
Blood
Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. [Abstract]2015 Jan 22;125(4):710-9. PMID: 25339356 -
Metabolism
Angiotensinogen inhibition concurrently mitigates alcohol-associated hepatic and muscle injury. [Abstract]2025 Apr 29:156275. PMID: 40311841 -
Redox Biol
AVE 0991 attenuates oxidative stress and neuronal apoptosis via Mas/PKA/CREB/UCP-2 pathway after subarachnoid hemorrhage in rats. [Abstract]2019 Jan;20:75-86. PMID: 30296700
AVE 0991 sodium salt purchased from MedChemExpress. Usage Cited in: Redox Biol. 2019 Jan;20:75-86. [Abstract]
AVE 0991 (AVE) treatment increases the expression of PKA-Cα, p-CREB, UCP-2, and Bcl-2, but the expression of Bax and Romo-1 are decreased in SAH+AVE group when compared with SAH+vehicle group.
-
Diabetes
Neprilysin Is Required for Angiotensin-(1-7)'s Ability to Enhance Insulin Secretion via Its Proteolytic Activity to Generate Angiotensin-(1-2). [Abstract]2017 Aug;66(8):2201-2212. PMID: 28559246 -
Biochem Pharmacol
A53T α-synuclein mutation increases susceptibility to postoperative delayed neurocognitive recovery via hippocampal Ang-(1-7)/MasR axis. [Abstract]2024 Jun:224:116261. PMID: 38705534 -
Front Aging Neurosci
The Non-peptide Angiotensin-(1-7) Mimic AVE 0991 Attenuates Delayed Neurocognitive Recovery After Laparotomy by Reducing Neuroinflammation and Restoring Blood-Brain Barrier Integrity in Aged Rats. [Abstract]2021 Feb 15:13:624387. PMID: 33658918 -
J Inflamm Res
Angiotensin-(1-7) Analogue AVE0991 Modulates Astrocyte-Mediated Neuroinflammation via lncRNA SNHG14/miR-223-3p/NLRP3 Pathway and Offers Neuroprotection in a Transgenic Mouse Model of Alzheimer's Disease. [Abstract]2021 Dec 18;14:7007-7019. PMID: 34955647 -
Sci Rep
AVE0991 ameliorates dopaminergic neuronal damage in Parkinson's disease through HOTAIRM1/miR-223-3p/α-synuclein axis. [Abstract]2024 Nov 1;14(1):26346. PMID: 39487232 -
Aging (Albany NY)
2018 Apr 17;10(4):645-657. PMID: 29667931 -
PLoS One
2015 Nov 5;10(11):e0142087. PMID: 26540167
AVE 0991 sodium salt purchased from MedChemExpress. Usage Cited in: PLoS One. 2015 Nov 5;10(11):e0142087. [Abstract]
The effect of AVE0991 on neuronal cell death following glucose deprivation. Data are shown for cells exposed to normal conditions (control) or glucose deprivation (vehicle) for 24 h or with (A) AVE0991 or (B) AVE0991+A779.
-
Exp Anim
Angiotensin 1-7 and its analogue decrease blood pressure but aggravate renal damage in preeclamptic mice. [Abstract]2022 Nov 10;71(4):519-528. PMID: 35934804 -
-
-
Solvant et solubilité
DMSO : 100 mg/mL (165.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (82.96 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocole
Mice[2]
Swiss male mice, Mas-KO (Mas-/-) male mice on the pure genetic background C57BL/6, and WT C57BL/6 control mice (Mas+/+) are used. Water diuresis is induced by intraperitoneal water injection (0.05 mL/g of body weight [BW]) in conscious mice. Drugs are administered in the same injection with water load at prefixed volumes (0.01 mL/g BW). In the first set of experiments, WT mice (C57BL/6, control group) or Mas-KO mice are treated with: (1) 0.58 nmol/g AVE 0991 (n=9, control; n=11, Mas-KO mice); or (2) vehicle for AVE 0991 (10 μM KOH, 0.01 mL/g; n=9, control; n=9, Mas-KO). In the second set, Swiss mice are treated with: (1) vehicle (n=36); (2) 0.58 nmol/g AVE 0991 (n=16); (3) 46 pmol/g Ang-(1-7) antagonist A-779 (n=4); (4) 2 nmol/g DuP-753 or CGP 48933 (n=5); (5) 2 nmol/g AT2 receptor antagonists PD123319 or PD123177 (n=9); (6) AVE 0991 combined with A-779; (7) AVE 0991 combined with DuP-753 or CGP 48933 (n=4 for each); (8) or AVE 0991combined with PD123319 (n=5) or PD123177 (n=4). The urinary volume is measured for 60 minutes after water loading, and urine samples are obtained to determine the osmolality. The dose of AVE 0991is based in preliminary experiments performed in Swiss mice.
Rats[3]
Male Wistar rats weighting 250-300 g are used. Rats are treated either with AVE-0991 (1 mg/kg, n=9) or vehicle (0.9% NaCl, n=11) administered orally by gavage.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Wiemer G, et al. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension. 2002 Dec;40(6):847-52. [Content Brief]
[2]. Pinheiro SV, et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004 Oct;44(4):490-6. [Content Brief]
[3]. Ferreira AJ, et al. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H1113-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.6592 mL | 8.2960 mL | 16.5920 mL | 41.4800 mL |
| 5 mM | 0.3318 mL | 1.6592 mL | 3.3184 mL | 8.2960 mL | |
| 10 mM | 0.1659 mL | 0.8296 mL | 1.6592 mL | 4.1480 mL | |
| 15 mM | 0.1106 mL | 0.5531 mL | 1.1061 mL | 2.7653 mL | |
| 20 mM | 0.0830 mL | 0.4148 mL | 0.8296 mL | 2.0740 mL | |
| 25 mM | 0.0664 mL | 0.3318 mL | 0.6637 mL | 1.6592 mL | |
| 30 mM | 0.0553 mL | 0.2765 mL | 0.5531 mL | 1.3827 mL | |
| 40 mM | 0.0415 mL | 0.2074 mL | 0.4148 mL | 1.0370 mL | |
| 50 mM | 0.0332 mL | 0.1659 mL | 0.3318 mL | 0.8296 mL | |
| 60 mM | 0.0277 mL | 0.1383 mL | 0.2765 mL | 0.6913 mL | |
| 80 mM | 0.0207 mL | 0.1037 mL | 0.2074 mL | 0.5185 mL | |
| DMSO | 100 mM | 0.0166 mL | 0.0830 mL | 0.1659 mL | 0.4148 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz